Microsatellite instability in aberrant crypt foci from patients without concurrent colon cancer

Emily J. Greenspan, Jennifer L. Cyr, Devon C. Pleau, Joel Levine, Thiruchandurai V. Rajan, Daniel W. Rosenberg, and Christopher D. Heinen

1Center for Molecular Medicine, 2Colon Cancer Prevention Program, Neag Comprehensive Cancer Center, 3Division of Gastroenterology and Hepatology, University of Connecticut Health Center, Farmington, CT USA
2Department of Immunology and Pathology, University of Connecticut Health Center, Farmington, CT USA

Abstract

Aberrant crypt foci (ACF) are microscopic surface abnormalities that are putative precursors to colorectal cancer (CRC). ACF exhibit similar histological and molecular abnormalities to adenomas and CRC and potentially represent useful biomarkers of cancer risk. Microsatellite instability (MSI) is one molecular abnormality identified in concurrent ACF from CRC patients that may indicate a risk for progression. To determine if MSI can be detected in ACF from cancer-free subjects, we examined 45 ACF from 20 subjects undergoing colonoscopies. The group included 12 patients at elevated risk for CRC based on family history of CRC or personal history of CRC or advanced adenoma and 8 patients with no known risk factors. ACF were identified using close-focus magnifying chromendooscopy and collected by biopsy in situ. Genomic DNA was prepared from ACF and adjacent normal colonic epithelium isolated by laser capture microdissection and analyzed for MSI. MSI was identified in at least one marker from 9 of 30 (30%) lesions from patients at elevated risk for CRC and in 2 of 15 (13%) lesions from average risk patients. Using methylation-specific PCR analysis, we also examined the ACF for promoter hypermethylation of the DNA repair genes hMLH1 and MGMT and found moderate changes (8/39 and 3/32, respectively). Although we found only a limited relationship between hMLH1 hypermethylation and MSI, all the lesions with MGMT hypermethylation displayed an MSI-low phenotype. These lesions may be precursors to MSI-low CRC, providing a potential early biomarker to assess the effects of cancer prevention strategies.

Introduction

Screening for early detection of colorectal adenomas is currently considered the most effective means of preventing colorectal cancer (CRC)-related death. Aberrant crypt foci (ACF) are postulated to be a precursor to the adenoma in the step-wise progression of CRC, and thus, potentially represent an earlier biomarker for cancer risk. ACF are microscopic surface abnormalities first identified in carcinogen-treated rodents and later in human colon (1,2). In animal models, ACF have been used as biomarkers to study the potency of colon carcinogens, as well as the effectiveness of chemopreventive agents (3). In human colon, they may also serve as a useful biomarker for determining cancer risk or response to cancer prevention strategies. With the advent of close focus high-magnification chromendooscopy, ACF can now be detected in situ and biopsied during a colonoscopy examination. This advance allows for a more complete characterization of these lesions to determine their suitability as a biomarker for CRC.

ACF display histologic features and molecular abnormalities in common with colonic adenomas and CRC supporting the notion that these lesions are the first step in the colon cancer progression pathway (3–8). An important question in the study of ACF is whether one can identify gross, histological or molecular features indicative of an increased risk for progression. Microsatellite instability (MSI) is one molecular abnormality identified in ACF that may indicate such a risk. MSI is a form of genomic instability at simple repeat sequences in the genome and is a hallmark of defective DNA mismatch repair (MMR) (9). MSI has been detected in 10–30% of sporadic CRC (10), as well as in greater than 95% of tumors from hereditary non-polyposis colon cancer (HNPCC) patients (11). Previous studies have identified MSI+ ACF (ACF that display instability of one or more microsatellite markers) from resected colon tissue obtained during surgery for a concurrent colon cancer (12–15). This observation suggests that loss of MMR function may occur very early in the tumorigenic process. However, as the ACF to carcinoma progression likely takes several years (16), MSI+ ACF should be detectable in patients in advance of cancer development.

The following study was undertaken to determine whether MSI+ ACF could be identified within the colons of individuals without a concurrent cancer by examining lesions biopsied in situ from patients undergoing screening or surveillance colonoscopy. Our data indicate that MSI can be detected in ACF from patients without a concurrent cancer. Interestingly, there is a slight increase in the percentage of MSI+ ACF in patients who had either (i) a previous advanced adenoma/colon cancer, or (ii) a first-degree relative with CRC compared to those with no known personal or family history of CRC. We also detected promoter hypermethylation of the DNA repair genes hMLH1 and MGMT in ACF. While we did not see a clear correlation between MSI and hMLH1 promoter methylation status, we did identify MSI in all ACF with MGMT promoter hypermethylation. By identifying these molecular aberrations in ACF from patients without a concurrent cancer, follow-up studies may be possible to determine the predictive value of these lesions for cancer risk.

Abbreviations: ACF, aberrant crypt foci; CRC, colorectal cancer; LOH, loss of heterozygosity; MSI, microsatellite instability; MSP, methylation-specific PCR.
Materials and methods

Subject selection

Two groups of patients were included in this study; those considered at elevated risk for CRC and those considered at average risk for CRC. Elevated risk was based on a positive family history (at least one first degree relative with the disease) and/or a positive personal history for CRC or advanced adenomas (17,18). Subjects designated as average risk for CRC indicated no personal or family history of CRC or benign polyps/adenomas. Patients suspected of having familial adenomatous polyposis or HNPCC (based on Amsterdam criteria) were excluded from this study. Patients underwent total colonoscopy at the John Dempsey Hospital (JDH) at the University of Connecticut Health Center (UCHC) in accordance with institutional policies. This study was performed after approval by an Institutional Review Board and all subjects provided written informed consent.

ACF collection and characterization

ACF were isolated from grossly normal appearing colonic mucosa by biopsy in situ during the high-resolution close-focus chroendoscopy portion of the total colonoscopy procedure performed in the JDH at UCHC. The distal 20 cm of colon including the rectum was examined after washing with 10–20 ml of 20% N-acetylcysteine followed by water wash to remove surface mucus. Then, a freshly prepared solution of 0.5% methylene blue was applied for contrast staining using spray catheters. After a waiting period of at least 2 min for vital dye–epithelial cell interaction, high volume water wash was applied. The maximum volume of the dye applied to the mucosa was 40 ml. Dye was only applied to the colorectal mucosa being studied. ACF were visualized and photographed using an Olympus Close Focus Colonoscope (XCF-Q160ALE), which enables visualization from 2 to 100 mm at a magnifying power of ×60 (Figure 1A and D) (7). Under close focus magnification, a finding was accepted as an ACF if 2 or more crypts had increased lumen diameter of 1.5 to ×2 compared to surrounding crypt lumens, if lumen shape was round, dilated or slit (non-hyperplastic), serrated (hyperplastic), or with thick crypt walls with compressed lumens (dysplastic). On tangential view, ACF were required to be raised above the mucosal surface. The endoscopist (J.L.) and two technicians trained in ACF image morphology observed the endoscopic image. The observers had to be in agreement that the lesion met the previously described criteria of ACF to be entered into study. Per protocol, a maximum of 12 biopsy specimens of ACF were taken within the distal 20 cm using forceps (Precisor EXL, CR Bard). Biopsies of individual ACF were embedded immediately in tissue freezing medium (OCT) and stored at −80°C. Frozen serial sections of ACF were prepared at 5–7 μm thickness on glass slides. Representative frozen sections of ACF were stained with hematoxylin and eosin for routine histological analysis by light microscopy of coded specimens by a pathologist (T.V.R.) (19,20).

DNA extraction

Frozen sections of ACF were stained and dehydrated using the Histogene staining kit (Molecular Devices, Sunnyvale, CA, USA), according to the manufacturer’s instructions. Laser capture microdissection (LCM) was performed on prepared sections using the Veritas LCM system (Molecular Devices). Whenever possible, adjacent normal mucosal cells directly abutting the aberrant crypts were collected separately by laser capture. On average, 1500–3000 cells were collected from each sample. DNA was extracted using the Picopure DNA extraction kit (Molecular Devices) and quantified using Picogreen (Molecular Probes, Eugene, OR, USA).

Cell lines and culture conditions

DNA was isolated from three established colon cancer cell lines, SW480, SW48 and RKO. RKO cells were grown in minimum essential medium (Eagle) (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (FBS) and 5% penicillin/streptomycin. SW480 and SW48 cells were grown in Dulbecco’s modified Eagle’s medium (Invitrogen), supplemented with 10% FBS and 5% penicillin/streptomycin.

MSI and loss of heterozygosity analysis

For MSI analysis, DNA was isolated from microdissected ACF and matched adjacent normal colon epithelia. MSI status was determined in all samples using the National Cancer Institute (NCI) recommended panel of five
microsatellite markers (BAT25, BAT26, D2S123, D5S346 and D17S250) (21) plus three additional microsatellite sequences found within the coding regions of TGFBR1, hMLH3 and hMSH6 (22). An ACF was considered to be MSI-high if three or more markers were positive for novel alleles compared to matched normal DNA. MSI-low if two or less markers were positive and microsatellite stable if none of the markers were positive.

PCR for all microsatellites were carried out using the forward oligonucleotide dye-labeled method using WellRED oligos (Promo📃, Boulder, CO, USA). DNA was amplified in 10 μl volumes containing 1× PCR buffer (Roche), 1 mmol each deoxynucleotide (Invitrogen), 0.25 U Taq polymerase (Invitrogen), 5 pmol of the forward fluorescently labeled primer (PromogetConfig, 5 pmol of the reverse primer (IDT) and 1 μl DNA. The cycling conditions were as follows: 95°C for 10 min, 16 cycles of 95°C for 30 s, 60°C for 45 s (decrease temperature 0.5°C/Cycle), 72°C for 30 s, 34 cycles of 94°C for 20 s, 50°C for 45 s, 72°C for 30 s, and a final elongation at 72°C for 10 min.

LOH was defined as an increase of the ratio of peak heights for the ACF sample compared to the normal control. The ratios of the heterozygous peak-heights were determined for both the normal and ACF samples. LOH was defined as an increase of >50% in the ratio of peak heights for the ACF sample compared to the normal control.

**Results**

**Patients and ACF histology**

A total of 45 ACF were biopsied from 20 patients (Table I) undergoing either routine screening colonoscopy or surveillance colonoscopy due to a clinical finding on a previous colonoscopy. This group included 12 patients described as at an elevated risk for colon cancer because of either a family history of colon cancer or at least one first degree relative or a personal history of colon cancer or advanced adenoma (17,18). Patients suspected of having either FAP or HNPPC (based on Amsterdam criteria) were not included in this study. The remaining eight patients indicated no known risk factors for colon cancer. The patients ranged in age from 43 to 86 years (average age = 60). ACF were identified and biopsied from the last 20 cm of the distal colon using a high-resolution close-focus colonoscope and methylene blue staining.

**Histopathology of ACF**

Microsatellite instability in aberrant crypt foci

The histopathology of ACF is generally classified into two major categories: hyperplastic and dysplastic (27). Hyperplastic ACF typically display characteristics similar to hyperplastic polyps, often displaying a distinct serrated crypt pattern (Figure 1) (7,20). All but two of the ACF analyzed in our study were hyperplastic, with one lesion being entirely dysplastic and one being composed of both dysplastic and hyperplastic-appearing crypts. While dysplastic ACF are generally better accepted as precursors to CRC, the significance of hyperplastic ACF in tumor progression is less well established (7,20).
promoter hypermethylation in up to 90% of sporadic MSI+ cancers (25,28–30). This epigenetic alteration is thought to be an early event in sporadic colon tumors that arise through a serrated, non-dysplastic adenoma (31,32). We identified hMLH1 promoter hypermethylation in 8 of 39 (21%) ACF examined (Table I). Whenever possible, we also tested genomic DNA from abutting normal mucosa. We did not find any promoter hypermethylation in normal crypts. Interestingly, we did not see a direct relationship between the presence of hMLH1 promoter hypermethylation and MSI, as only two of our MSI+ ACF displayed hypermethylation.

Jass and co-workers have posited an association between the MSI-low phenotype and promoter hypermethylation of MGMT (33). MGMT is a DNA repair enzyme that removes deleterious methyl adducts from guanine residues. An accumulation of these aberrantly methylated guanines has been shown to activate a MMR-dependent DNA damage response (34), giving rise to the speculation that loss of MGMT in tumors may cause the MMR system to be temporarily overwhelmed resulting in an MSI-low phenotype (33). We tested a subset of our ACF for MGMT promoter hypermethylation and report that 3 of 32 (9%) demonstrated hypermethylation (Figure 3C and D, Table I). All three of these ACF displayed an MSI-low phenotype. Similar to hMLH1, we did not see any MGMT promoter hypermethylation in adjacent normal crypts.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>History</th>
<th>Sample</th>
<th>ACF histology</th>
<th>MSI</th>
<th>Methylation</th>
<th>LOH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>hMLH1</td>
<td>MGMT</td>
</tr>
<tr>
<td>Elevated risk patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>86</td>
<td>Ad</td>
<td>042004-1130-3</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>2</td>
<td>74</td>
<td>Ad</td>
<td>112003-1045-4</td>
<td>Hyperplasia</td>
<td>MSI-L</td>
<td>M</td>
<td>ND</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>Ad</td>
<td>021904-1000-2</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>4</td>
<td>49</td>
<td>FHx</td>
<td>121103-1100-1</td>
<td>Dysplasia</td>
<td>MSI-L</td>
<td>U</td>
<td>M</td>
</tr>
<tr>
<td>5</td>
<td>80</td>
<td>Ad</td>
<td>042604-1130-1</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>6</td>
<td>56</td>
<td>Ad</td>
<td>01905-930-4</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>M</td>
<td>U</td>
</tr>
<tr>
<td>7</td>
<td>43</td>
<td>FHx</td>
<td>101804-1100-2</td>
<td>Hyperplasia</td>
<td>MSI-L</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>8</td>
<td>79</td>
<td>Ad</td>
<td>101104-1130-4</td>
<td>Hyperplasia</td>
<td>MSI-L</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>9</td>
<td>76</td>
<td>CRC/FHx</td>
<td>052704-1130-4</td>
<td>Hyperplasia</td>
<td>MSI-L</td>
<td>U</td>
<td>M</td>
</tr>
<tr>
<td>10</td>
<td>73</td>
<td>Ad</td>
<td>052704-900-2</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>11</td>
<td>56</td>
<td>Ad</td>
<td>080105-945-2</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>ND</td>
</tr>
<tr>
<td>12</td>
<td>46</td>
<td>FHx</td>
<td>071204-1130-3</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>Average risk patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>52</td>
<td>None</td>
<td>2-2</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>ND</td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td>None</td>
<td>3-2</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>3</td>
<td>58</td>
<td>None</td>
<td>8-3</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>4</td>
<td>52</td>
<td>None</td>
<td>14-2</td>
<td>Hyperplasia</td>
<td>MSI-H</td>
<td>U</td>
<td>U</td>
</tr>
<tr>
<td>5</td>
<td>57</td>
<td>None</td>
<td>16-2</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>None</td>
<td>24-2</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>ND</td>
</tr>
<tr>
<td>7</td>
<td>59</td>
<td>None</td>
<td>40-4</td>
<td>Hyperplasia</td>
<td>MSS</td>
<td>U</td>
<td>U</td>
</tr>
</tbody>
</table>

*Reason for elevated risk status. Ad = advanced adenoma, CRC = colorectal cancer, FHx = family history.

*MSI status. MSS = microsatellite stable (instability at 0 markers tested); MSI-L = microsatellite instability-low (instability at 1 or 2 markers tested); MSI-H = microsatellite instability-high (instability at 3 or more markers tested).

*Methylation status. M = promoter methylated by MSP; U = promoter unmethylated by MSP; ND = not determined.
LOH identified in ACF

Microsatellite analysis can also be used to assay for LOH. We identified LOH events in two ACF, both from the elevated risk group (Figure 4, Table 1). These LOH events occurred at the DSS346 marker which is near the APC tumor suppressor gene.

Discussion

The step-wise progression of CRC from normal mucosa to invasive carcinoma is a process that occurs over many years (16). The ability to recognize the earliest stages of this process may allow for therapeutic intervention to be undertaken that prevents progression to debilitating disease. Although it is widely accepted that adenomas are precursors to CRC, it is unclear what early changes within the colorectal mucosa constitute a bona fide precursor to the adenoma. ACF are generally considered the earliest, identifiable morphological change in the colon, and there is evidence to support the notion that ACF represent CRC precursor lesions (3). As an example, ACF exhibit many of the molecular and genetic abnormalities that form the basis for the adenoma–carcinoma sequence in CRC (7,35). Many of these alterations were discovered in ACF removed during surgery for a concurrent CRC. With the advent of high-resolution, close-focus colonoscopy, it is now possible to identify and biopsy ACF in situ allowing for analysis of ACF from patients who have not developed, though may be at risk for developing, CRC.

We report here the identification of MSI in ACF from patients without a concurrent colon cancer. There is an increase in the percentage of MSI+ ACF in patients with a known risk factor for CRC—either a personal history of CRC or advanced adenoma or a family history of CRC in a first-degree relative. First-degree relatives of patients with sporadic CRC have been reported to exhibit an increased risk of developing colon tumors, and this risk increases as the number of affected relatives increases (36). Although the increase we observed in the percentage of MSI+ ACF is not statistically significant ($P \leq 0.25$), it will be interesting to determine whether this trend continues by examining more patients and lesions.

Almost all of the ACF examined in our study, including all but one of the MSI+ ACF, were hyperplastic ACF. The hyperplastic ACF could be the precursor to the hyperplastic polyp that develops during the course of a serrated pathway of sporadic CRC (32). The serrated pathway results in adenocarcinomas typically marked by the presence of MSI, as well as high levels of CpG island methylation in promoter regions of tumor suppressor genes (37). The serrated pathway may include two separate mechanisms that give rise to either MSI-high or MSI-low cancers. Loss of hMLH1 expression due to promoter hypermethylation is commonly observed in MSI-high cancers and some serrated adenomas (38). We have observed hMLH1 promoter hypermethylation in 8 of 39 ACF. Promoter hypermethylation was never seen in DNA from abutting normal crypts, arguing that this phenomenon is not part of a field effect, but is specific to the lesion. Only two of eight ACF with hMLH1 promoter hypermethylation displayed MSI. Of the 31 lesions that did not have hypermethylation, 6 displayed MSI, suggesting a lack of significant association in ACF ($P \leq 0.9$). This finding is consistent with a previous report that identified promoter hypermethylation of hMLH1 in two ACF that were both MSS (15).

The majority of MSI+ ACF identified in the present study were found to be MSI-low. These ACF may represent the earliest stage in an MSI-low cancer pathway. The existence of a separate pathway of tumorigenesis characterized by an MSI-low phenotype has been controversial. The idea stems from observations that tumors with an MSI-low phenotype display different molecular characteristics than MSI-high cancers (33,39,40). One molecular feature of MSI-low cancers is hypermethylation of the MGMT promoter (33). We identified MGMT promoter hypermethylation in 3/7 MSI-low ACF tested while detecting no hypermethylation in the MSS or MSI-H lesions tested, suggesting an association between MGMT promoter hypermethylation and an MSI-L phenotype ($P \leq 0.01$). Loss of MGMT activity may lead to an increase in the number of highly mutagenic 6-methylguanine lesions in the DNA which, when mispaired with a thymine, activate the MMR pathway (34). Jass et al. (32) have proposed that increases in 6-MeG/T lesions may temporarily overwhelm the MMR system resulting in a transitory mutator phenotype resulting in MSI-L lesions. In general, the nature of the MSI-L phenotype is not clear. While the temporary overwhelming of the MMR pathway is an intriguing model, MSI-L lesions also could potentially arise due to mutations in repair genes that result in a weaker mutator phenotype. As an example, mutations in hMSH6, another MMR gene mutated in a small fraction of HNPCC cases, have been proposed to result in a greater frequency of tumors with MSI-L phenotype (41).

Surprisingly, the frequency of MSI+ ACF identified in the present study was somewhat higher than that reported in previous studies of ACF isolated from patients with synchronous cancer (12–14). One possible explanation may be that we are using LCM to isolate aberrant crypts from surrounding stroma and normal mucosa. This technique may
Fig. 3. *hMLH1* and *MGMT* promoter hypermethylation as determined by methylation-specific PCR. (A and C) Maps of the *hMLH1* and *MGMT* gene promoter regions, respectively, and detail of the CpG islands used for analysis of promoter methylation by MSP (ovals). Arrows marked ‘ex for’ and ‘ex rev’ represent the locations of the flanking PCR primers used to amplify a 376 bp template for the *hMLH1* MSP and 342 bp template for *MGMT* MSP. Boxes marked ‘MSP for’ and ‘MSP rev’ represent the locations of the methylation-specific primers used to amplify either the methylated promoter (*hMLH1* = 115 bp product; *MGMT* = 81 bp product) or unmethylated promoter (*hMLH1* = 124 bp product; *MGMT* = 93 bp product). (B) Representative examples of MSP of *hMLH1* promoter in ACF. MSP was performed using methylation-specific (M) and unmethylation-specific (U) primer sets as detailed in Materials and methods. The presence of a visible PCR product in the lanes marked M indicates the presence of methylated alleles. All samples have variable degrees of amplification with the U primers, most likely due to stromal cell contamination. RKO cells have a fully methylated *hMLH1* promoter and SW480 cells have a fully unmethylated promoter. ACF1 = patient 3, sample 021904-100-2; ACF2 = patient 10, sample 052704-900-2; ACF3 = patient 9, sample 052704-1130-4; ACF4 = patient 9, sample 052704-1130-5; ACF5 = patient 4, sample 121103-1100-2; N5 = the abutting normal mucosa to ACF5. (D) As per in (B), representative examples of MSP of *MGMT* promoter in ACF. SW48 cells have a fully methylated *MGMT* promoter and RKO cells have a fully unmethylated promoter. ACF1 = patient 3, sample 021904-1000-5; N2 = the abutting normal mucosa to ACF2; ACF2 = patient 4, sample 121103-1100-2; ACF3 = patient 4, sample 121103-1100-1.
LOH was identified in two separate ACF, both at the D5S346 marker on chromosome 5 near the APC tumor suppressor gene. (A) LOH identified from elevated risk patient #3, sample 021904-1000-4. (B) LOH identified from elevated risk patient #7, sample 101804-100-6. Lost allele indicated by arrows.

Fig. 4. LOH in ACF at a marker near the APC tumor suppressor.

LOH was identified in two separate ACF, both at the D5S346 marker on chromosome 5 near the APC tumor suppressor gene. (A) LOH identified from elevated risk patient #3, sample 021904-1000-4. (B) LOH identified from elevated risk patient #7, sample 101804-100-6. Lost allele indicated by arrows.

increase the sensitivity of our assays, allowing us to detect MSI events that may otherwise have been masked by contaminating DNA from normal cells (42). In addition, all of our biopsied ACF were from the distal 20 cm of the colon. Previous studies focused predominantly on right-sided ACF, where most MSI-high CRC have been located. Some right-sided ACF may not have developed MSI as the MSI-high phenotype appears to arise later in the tumorigenic process (15,39). However, MSI-low cancers and serrated adenomas are typically found on the left side (43). That we find MSI-low ACF more abundantly than MSI-high lesions in the left colon is consistent with these observations and supports the hypothesis that these lesions represent precursors to MSI-low CRC. It is evident, however, that the majority of ACF, even those lesions displaying MSI, do not progress to a carcinoma, or even to an adenoma. In fact, half of all patients have at least one ACF by the time they are 50 years old, and the prevalence and total number of ACF in each patient increases with age (7). Thus, the alternative hypothesis must be considered; that MSI+ ACF, displaying either high or low instability, are less likely to progress to cancer.

Ultimately, the most important clinical question will be to determine whether the presence of MSI+ ACF identified in human subjects offers useful prognostic information regarding cancer risk. While it is neither practical nor even necessary to identify and remove all ACF in every patient who undergo a routine colonoscopy procedure, further studies examining ACF in subsets of patients might lead to information about the effectiveness of chemoprevention agents or other prevention strategies that can halt the tumorigenic process at an early stage.

Acknowledgments

We thank Richard G.Stevens for helpful discussions regarding this article. We thank the Ye’lin Golf Foundation and the V Foundation for their generous support and the Olympus Corporation for generously providing the endoscopy instrumentation. This project also was supported by NIH grant CA-81428 (D.W.R.).

Conflict of Interest Statement. None declared.

References


Received July 21, 2006; revised September 27, 2006; accepted October 23, 2006